Another step forward in blood-based diagnostics for Alzheimer’s disease

Measurement of phosphorylated tau protein in blood plasma allows Alzheimer’s disease to be distinguished from other neurological diseases and may assist in disease detection during the prodromal stage.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: p-tau181 can be used as a prognostic and confirmatory biomarker for AD.


  1. 1.

    Bateman, R. J. et al. N. Engl. J. Med. 367, 795–804 (2012).

    CAS  Article  Google Scholar 

  2. 2.

    Janelidze, S. et al. Nat. Med. (2020).

    Article  PubMed  Google Scholar 

  3. 3.

    Thijssen, E. H. et al. Nat. Med. (2020).

    Article  PubMed  Google Scholar 

  4. 4.

    Sato, C. et al. Neuron 97, 1284–1298.e7 (2018).

    CAS  Article  Google Scholar 

  5. 5.

    Barthélemy, N. R., Horie, K., Sato, C. & Bateman, R. J. J. Prev. Alzheimers Dis. 6, S34–S35 (2019).

    Google Scholar 

  6. 6.

    Barthélemy, N. R., Mallipeddi, N., Moiseyev, P., Sato, C. & Bateman, R. J. Front. Aging Neurosci. 11, 121 (2019).

    Article  Google Scholar 

  7. 7.

    Nakamura, A. et al. Nature 554, 249–254 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Ovod, V. et al. Alzheimers Dement. 13, 841–849 (2017).

    Article  Google Scholar 

  9. 9.

    Schindler, S. E. et al. Neurology 93, e1647–e1659 (2019).

    CAS  PubMed  Google Scholar 

  10. 10.

    Preische, O. et al. Nat. Med. 25, 277–283 (2019).

    CAS  Article  Google Scholar 

  11. 11.

    Mielke, M. M. et al. Alzheimers Dement. 14, 989–997 (2018).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Randall J. Bateman.

Ethics declarations

Competing interests

Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (blood plasma assay) licensed by Washington University to C2N Diagnostics, and R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University has submitted the US provisional patent application ‘Plasma Based Methods for Detecting CNS Amyloid Deposition’ (co-inventor, R.J.B.) and the US non-provisional patent application ‘Methods of Diagnosing and Treating Based on Site-Specific Tau Phosphorylation’ (co-inventors, R.J.B. and N.R.B.).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bateman, R.J., Barthélemy, N.R. & Horie, K. Another step forward in blood-based diagnostics for Alzheimer’s disease. Nat Med 26, 314–316 (2020).

Download citation

Further reading